Vitrolife: IVF Products Approved in Russia
Vitrolife has obtained approval for its IVF nutrient solutions in Russia. Approval comprises 35 products.
“Russia is one of the markets that we have decided to focus on. Penetration for IVF is relatively low today, but it is assessed that this market can grow faster than average during the coming years" says Nils Sellbom, Director of Sales at Vitrolife.14,000 infertility treatments are today carried out each year in Russia and the number of fertility clinics amounts to approximately 50. The potential market value for nutrient solutions and instruments for IVF thereby amounts to approximately SEK 30 million today.
Vitrolife is a global biotechnology/medical device group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation.
Vitrolife today has approximately 140 employees and the company´s products are sold in more than 80 markets.
The head office is in Kungsbacka, Sweden, and there are subsidiaries in Sweden, USA, Australia and Italy. The Vitrolife share is listed on the OMX Nordic Exchange's Nordic Small Cap list.
